Skip to main content

Table 3 Role of m6A regulator in radiotherapy and immunotherapy

From: Emerging roles of m6A RNA modification in cancer therapeutic resistance

Drug

Regulator

Role

Level

Cancer

Target

Effect

Refs.

irradiation

METTL3

Oncogene

High

GBM

Pol kappa

regulates its localization to DNA damage sites

[130]

irradiation

METTL3

Oncogene

High

GBM

SOX2

Increases stability of SOX2 mRNA

[131]

irradiation

FTO

Oncogene

High

CSCC

β-catenin

Promotes expression of β-catenin

[132]

irradiation

ALKBH5

Oncogene

High

GBM

CHK1, Rad51

Promotes expression of CHK1 and Rad51

[133]

Anti-PD1

METTL3/14

Oncogene

High

CRC

STAT1, IRF1

stabilizing the STAT1 and IRF1 mRNA via YTHDF2 [135]

[135]

Anti-PD1

METTL14

Suppressor

NA

CCA

SIAH2

Promotes the degradation of SIAH2 mRNA via YTHDF1

[136]

Anti-PD1

YTHDF1

Oncogene

NA

Melanoma

cathepsins

Promotes the translation of lysosomal cathepsins

[137]

Anti-PD1

FTO

Oncogene

High

Melanoma

PD-1, CXCR4, SOX10

Reduces the degradation of PD-1, CXCR4, and SOX10 mRNAs

[138]

Anti-PD1

FTO

Oncogene

High

CRC

PD-L1

Promotes expression of PD-L1

[139]

Anti-PD1

ALKBH5

Oncogene

NA

Melanoma

MCT4

Promotes expression of MCT4

[140]